Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial

2014 San Antonio Breast Cancer Symposium

Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive axillary nodes who convert to ypN0 after neoadjuvant chemotherapy? NSABP B-51/RTOG 1304 a phase III trial.”

Hope S. Rugo, MD, on Dietary Intervention as Adjuvant Breast Cancer Therapy

Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S5-08, “Final survival analysis from the randomized Women's Intervention Nutrition Study (WINS) evaluating dietary intervention as adjuvant breast cancer therapy,” presented by Rowan T. Chlebowski, MD.

Breast Cancer

Jack Cuzick, PhD

Jack Cuzick, PhD, on the IBIS-I Trial

Jack Cuzick, PhD, of the Wolfson Institute of Preventive Medicine, discusses abstract S3-07, "16-year long-term follow-up of the IBIS-I breast cancer prevention trial."

Breast Cancer

William J. Gradishar, MD, and Edith A. Perez, MD

William J. Gradishar, MD, and Edith A. Perez, MD, on Immunotherapy and highlights of the Bolero-1 and SOFT Trials

William J. Gradishar, MD, of Northwestern University, and Edith A. Perez of the Mayo Clinic Cancer Center, discuss immunotherapy and the highlights of the BOLERO-1 and SOFT trials.

Breast Cancer

Harold J Burstein MD PhD and Lisa A Carey MD

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:

The TNT trial comparing docetaxel to carboplatin
The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab
Pembrolizumab in a phase Ib study

Breast Cancer

Clifford A. Hudis, MD, FACP

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.

Aug

Today In Oncology

Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial

Related Videos

Hope S. Rugo, MD, on Dietary Intervention as Adjuvant Breast Cancer Therapy

Jack Cuzick, PhD, on the IBIS-I Trial

William J. Gradishar, MD, and Edith A. Perez, MD, on Immunotherapy and highlights of the Bolero-1 and SOFT Trials

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Large Multicenter Study Evaluates LITT for Primary and Metastatic Brain Tumors

Tissue-Free ctDNA Assay May Help Identify Recurrence Risk in Early Triple-Negative Breast Cancer

Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer

In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles

cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions